NASDAQ GS | VYGR (Common Stock)


0.00 (0.00%)

Data as of: 08/26/16  4:00 p.m. ET

Investor Overview

Corporate Profile

Voyager Therapeutics is developing life-changing gene therapies for fatal and debilitating diseases of the central nervous system. Our founders include scientific and clinical leaders in the fields of adeno-associated virus (AAV) gene therapy, expressed RNA interference and neuroscience. Our management team has deep expertise and a track record of building exceptional life science companies. More >>

Recent NewsMore >>
August 12, 2016
Voyager Therapeutics to Attend Upcoming Investor Conferences
August 11, 2016
Voyager Therapeutics Provides Second Quarter 2016 Investor Update
August 09, 2016
Voyager Therapeutics Initiates Third Cohort in Ongoing Phase 1b Clinical Trial of VY-AADC01 in Advanced Parkinson’s Disease
Upcoming EventsMore >>
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.